Kirk Robarge

2.3k total citations
26 papers, 1.0k citations indexed

About

Kirk Robarge is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Kirk Robarge has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Organic Chemistry and 4 papers in Computational Theory and Mathematics. Recurrent topics in Kirk Robarge's work include Carbohydrate Chemistry and Synthesis (6 papers), Computational Drug Discovery Methods (4 papers) and Melanoma and MAPK Pathways (4 papers). Kirk Robarge is often cited by papers focused on Carbohydrate Chemistry and Synthesis (6 papers), Computational Drug Discovery Methods (4 papers) and Melanoma and MAPK Pathways (4 papers). Kirk Robarge collaborates with scholars based in United States, France and China. Kirk Robarge's co-authors include Fillmore Freeman, Dale L. Boger, Robert L. Yauch, Frédéric J. de Sauvage, Stephen E. Gould, Richard Goldsmith, Brent Blackburn, Zora Modrušan, Gerrit J.P. Dijkgraaf and Dan Burdick and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Kirk Robarge

26 papers receiving 954 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Kirk Robarge 664 370 143 97 78 26 1.0k
Vito Guagnano 896 1.3× 343 0.9× 380 2.7× 80 0.8× 55 0.7× 30 1.4k
Vishal Pendharkar 714 1.1× 137 0.4× 270 1.9× 62 0.6× 47 0.6× 15 1.0k
Rooha Contractor 870 1.3× 214 0.6× 469 3.3× 70 0.7× 92 1.2× 24 1.3k
Masanori Okaniwa 886 1.3× 250 0.7× 229 1.6× 59 0.6× 25 0.3× 26 1.4k
Yoshiharu Mizui 1.2k 1.9× 304 0.8× 118 0.8× 41 0.4× 96 1.2× 27 1.6k
Brad O. Buckman 391 0.6× 407 1.1× 169 1.2× 46 0.5× 123 1.6× 37 986
Neil Wishart 231 0.3× 259 0.7× 132 0.9× 53 0.5× 120 1.5× 21 799
Indrasish Ray Chaudhuri 642 1.0× 250 0.7× 244 1.7× 23 0.2× 72 0.9× 26 1.1k
Peter Drueckes 727 1.1× 173 0.5× 290 2.0× 29 0.3× 118 1.5× 24 1.2k
Nicole Streiner 1.1k 1.7× 159 0.4× 312 2.2× 36 0.4× 53 0.7× 16 1.4k

Countries citing papers authored by Kirk Robarge

Since Specialization
Citations

This map shows the geographic impact of Kirk Robarge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Robarge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Robarge more than expected).

Fields of papers citing papers by Kirk Robarge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Robarge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Robarge. The network helps show where Kirk Robarge may publish in the future.

Co-authorship network of co-authors of Kirk Robarge

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk Robarge. A scholar is included among the top collaborators of Kirk Robarge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk Robarge. Kirk Robarge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fauber, Benjamin P., Alberto Gobbi, Kirk Robarge, et al.. (2015). Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists. Bioorganic & Medicinal Chemistry Letters. 25(15). 2907–2912. 58 indexed citations
2.
Robarge, Kirk, Wendy Lee, Charles Eigenbrot, et al.. (2014). Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479. Bioorganic & Medicinal Chemistry Letters. 24(19). 4714–4723. 32 indexed citations
3.
Gould, Stephen E., Jennifer A. Low, James C. Marsters, et al.. (2014). Discovery and preclinical development of vismodegib. Expert Opinion on Drug Discovery. 9(8). 969–984. 54 indexed citations
4.
Fauber, Benjamin P., Peter S. Dragovich, Jinhua Chen, et al.. (2014). Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase. Bioorganic & Medicinal Chemistry Letters. 24(24). 5683–5687. 17 indexed citations
5.
Lee, Wendy, Daniel F. Ortwine, Philippe Bergeron, et al.. (2013). A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(18). 5097–5104. 26 indexed citations
6.
Choo, Edna F., Marcia Belvin, Jason Boggs, et al.. (2012). Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions. Drug Metabolism and Disposition. 40(5). 919–927. 28 indexed citations
7.
Choo, Edna F., Marcia Belvin, Jason Boggs, et al.. (2012). 502 Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623. European Journal of Cancer. 48. 155–155. 2 indexed citations
8.
Dijkgraaf, Gerrit J.P., Bruno Alicke, Lasse Weinmann, et al.. (2010). Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance. Cancer Research. 71(2). 435–444. 293 indexed citations
9.
Choo, Edna F., Marcia Belvin, Jocelyn Chan, et al.. (2010). Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor. Xenobiotica. 40(11). 751–762. 17 indexed citations
10.
11.
Olivero, Alan G., Charles Eigenbrot, Richard Goldsmith, et al.. (2005). A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo. Journal of Biological Chemistry. 280(10). 9160–9169. 36 indexed citations
12.
Shahrokh, Zahra, Eric Wai Ming Lee, Alan G. Olivero, et al.. (1998). Stability of alkoxycarbonylamidine prodrugs.. Pharmaceutical Research. 15(3). 434–441. 7 indexed citations
13.
Robarge, Kirk, Michael S. Dina, Todd C. Somers, et al.. (1998). Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorganic & Medicinal Chemistry. 6(12). 2345–2381. 11 indexed citations
14.
Modi, Nishit B., Sherron Bullens, Michael T. Lipari, et al.. (1998). Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form. Thrombosis and Haemostasis. 79(1). 169–176. 22 indexed citations
15.
McDowell, Robert S., Brent Blackburn, Thomas R. Gadek, et al.. (1994). From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold. Journal of the American Chemical Society. 116(12). 5077–5083. 82 indexed citations
16.
Webb, Robert R., Peter L. Barker, Mark E. Reynolds, et al.. (1994). Mono-N-alkylation of anthranilamides via quinazolinones. An efficient synthesis of G5598, a benzodiazepine dione gpIIbIIIa antagonist. Tetrahedron Letters. 35(14). 2113–2116. 29 indexed citations
17.
Freeman, Fillmore & Kirk Robarge. (1989). Stereoselectivity in electrophile-mediated intramolecular cyclizations of hept-2-enitols. The Journal of Organic Chemistry. 54(2). 346–359. 18 indexed citations
18.
19.
Freeman, Fillmore & Kirk Robarge. (1986). Epimerization at C-2 during the Wittig reaction of 2,3,5-tri-O-benzyl-d-ribose and methylidenetriphenylphosphorane. Carbohydrate Research. 154(1). 270–274. 22 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vito Guagnano Breakdown of academic impact, for papers by Vishal Pendharkar Breakdown of academic impact, for papers by Rooha Contractor Breakdown of academic impact, for papers by Masanori Okaniwa Breakdown of academic impact, for papers by Yoshiharu Mizui Breakdown of academic impact, for papers by Brad O. Buckman Breakdown of academic impact, for papers by Neil Wishart Breakdown of academic impact, for papers by Indrasish Ray Chaudhuri Breakdown of academic impact, for papers by Peter Drueckes Breakdown of academic impact, for papers by Nicole Streiner
Rankless by CCL
2026